Search results for #TumourEvolution
.@weiwei_beijing @Xiaodong_Liu1 @LiangMa_IOZ analyse #TumourEvolution in spatially-sampled #HepatocellularCarcinoma, infer evolutionary forces that shape spatial heterogeneity #CancerResearch @NatResCancer nature.com/articles/s4146…
🔬👩🔬We’re excited to share another commercial opportunity! @AndreaSottoriva, leader of the Evolutionary #Genomics and Modelling team, is keen to collaborate with partners to develop a method of determining and tracking #TumourEvolution. More here: icr.ac.uk/working-with-i…
Join us in congratulating another @CancerGrand winner – meet the eDyNAmiC team! They’ve received a £20m award to tackle the challenge of #ecDNA and #tumourevolution – curious to find out more? Visit their page tinyurl.com/nhcbrnc6 + keep reading ⬇️ ⬇️
Congratulations to the @CancerGrand eDyNAmiC team, led by @mischellab @StanfordMed, announced today to receive a £20m award to take on the challenge of #ecDNA and #tumourevolution. Co-founded by @CR_UK & @theNCI #CancerGrandChallenges bit.ly/3zE45Ct
We can't wait to hear about the latest research on #tumourevolution and #therapyresistance from our Keynote speaker Prof Chris Marine from @lab_marine and @VIBLifeSciences Center for Cancer Biology at our 5th Scientific Symposium. Registrations open soon: ozmrs.com/ozmrs-symposium
New post-doc and RA positions in our Tumour Evolution and Cell Identity Lab. @UniofOxford @NDSurgicalSci my.corehr.com/pls/uoxrecruit… my.corehr.com/pls/uoxrecruit… #organoids #CRISPR #scRNAseq #tumourevolution
It is #SarcomaAwarenessMonth! Check out the great line-up of talks this month in our weekly #SarcomaWebinar series covering the topics of #ArtificialIntelligence, #Genomics, #TumourEvolution, and #TargetedTreatment in #Sarcoma Joining details at: tiny.cc/0ziynz (1/2)
Looking forward to a busy week ahead at Moffitt Cancer Center! #moffittIMO #research #tumourevolution #USA #Florida @mathonco @MoffittPSOC @MoffittNews @ara_anderson
Using HSP90i in combination to restrict tumour options for acquiring resistance to pathway inhibitors of HSP90-dependent targets has to be the way to go - more trials of this type needed @CRUKresearch @ICR_London #TumourEvolution
Using HSP90i in combination to restrict tumour options for acquiring resistance to pathway inhibitors of HSP90-dependent targets has to be the way to go - more trials of this type needed @CRUKresearch @ICR_London #TumourEvolution
Pfuderer and colleagues have an article investing the contribution of lymphocyte trafficking in #ColorectalCancer publishing today. Take a look here: go.nature.com/2GBNxPg #immunoediting #tumourevolution #lynchsyndrome
Huge thank you to @CharlesSwanton of @TheCrick for being our #keynotespeaker today. Fantastic talk about #tumourevolution and immune evasion. #ChainFlorey
Great start with @CharlesSwanton reviewing insights into #TumourEvolution from #TRACERx, PEACE and associated studies, and potential implications for treatment strategies at #NCRI2018
Discuss the latest in Lung #immunoOncology, #TumourEvolution & more - a few places left: cruk.org/lungconf?utm_s… #LungCancer #WCLC2017 #LCSM
Consensus statement on #tumourevolution terms in @NatureRevCancer ensuring we're all speaking the same language! nature.com/nrc/journal/v1…
We're now looking at #TumourEvolution with @CharlesSwanton - starting with Paul Workman talking about team science at the ICR. #ncri2016